AAO 2024 Insights: Subcutaneous VRDN-003 vs. Veligrotug (VRDN-001), Full Antagonist Monoclonal Antibodies to IGF-1R for Thyroid Eye Disease - Phase 1 Safety/PK/PD Studies in Healthy Volunteers